Employees at Samsung Biologics have voted decisively in favour of industrial action, marking a significant escalation in tensions between the workforce and management. The ballot, held over six days in late March, saw an overwhelming majority support the move, with participation levels also notably high. The result comes after mediation efforts by the Incheon Regional Labour Relations Commission were formally concluded, clearing the legal path for a strike.
The labour union, which represents a large share of the company’s workforce, has framed the issue as far more than a disagreement over wages. It points to deeper concerns around corporate governance, workplace practices, and environmental, social and governance (ESG) standards. According to the union, several allegations—ranging from unfair labour practices to the handling of employee data—remain unresolved, raising broader compliance risks.
A key flashpoint has been the company’s approach to wage negotiations. Despite reporting strong financial growth, the management is said to have followed a standardised pay guideline set at the group level by Samsung Electronics, rather than negotiating based on the subsidiary’s individual performance. This has fuelled criticism over limited decision-making autonomy within the organisation.
The dispute is now being viewed as a potential operational risk, particularly given the company’s role in the global contract development and manufacturing sector. Prolonged unrest could impact supply chains serving international clients.
Union leaders have indicated that, in the absence of a revised proposal from management, a phased escalation will begin. This is expected to start with a large rally in April, followed by the possibility of a full-scale strike in early May.
